Clinically reviewed by Dr. Sarah Boss, MD
Suspected lithium toxicity requires withholding lithium and urgent medical assessment. Stop agomelatine and seek urgent advice if signs of liver injury develop. New jaundice, markedly reduced urine, severe confusion, collapse or serious breathing difficulty needs prompt or emergency assessment according to severity.
Kidney and liver health can change how a medicine is handled and which treatment is appropriate. They also matter when investigating new fatigue, confusion, nausea or other symptoms during psychiatric care. A review should connect laboratory results with the person’s actual medicines, physical health and treatment goals. It should not turn one abnormal number into a self-directed dose change or assume every symptom is a medication effect.
Clearance and organ injury are different questions
A medicine may need adjustment because the body clears it more slowly, even when that medicine did not cause the underlying kidney or liver condition. Separately, some medicines can themselves contribute to organ injury. Distinguishing these questions helps avoid the assumption that every renal adjustment proves a drug has damaged the kidneys.
Ask the clinician what the concern actually is: reduced clearance, a possible adverse reaction, an interaction or another illness. The answer affects whether the plan involves monitoring, investigation, a different regimen or urgent treatment. A useful explanation should connect the test result to a clinical decision rather than simply describe a medicine as hard on the organs.
Start with the complete regimen
Bring prescriptions, non-prescription medicines, supplements and occasional products into the review. Include painkillers, sleeping tablets, herbal preparations and medicines obtained elsewhere. The amount actually taken matters, not only the amount printed on a prescription. Recent starts and stops can also change the interpretation of symptoms or blood results.
List the reason for each medicine and the clinician responsible. A psychiatrist may not automatically know about a new diuretic, antibiotic or pain prescription. Likewise, a renal or liver specialist needs to know about psychiatric treatment and the consequences of changing it. The aim is one coordinated plan rather than separate decisions made from incomplete lists.
Understanding kidney tests
Kidney assessment can involve blood creatinine, estimated filtration and urine testing. Chronic kidney disease is not diagnosed or staged from symptoms alone. The NHS describes the use of blood and urine results together, including estimated glomerular filtration rate and urine albumin measurements. Trends and the wider clinical picture matter. [1]
Ask which result is being used and whether it is stable. A value from before an acute illness may not describe current function. Do not use a single online threshold to decide how much psychiatric medicine to take. The prescribing information for the specific product and the clinician’s assessment should guide any adjustment.
Why kidney-function estimates are not interchangeable
Estimated glomerular filtration rate and estimated creatinine clearance are related but different measures. Their limitations include the effects of muscle mass, body size and changing creatinine during acute illness. NHS Specialist Pharmacy Service explains that the appropriate calculation depends on the medicine and the circumstances. [2]
This matters particularly when a medicine has a narrow safety margin or relies substantially on renal elimination. The patient should not be expected to choose a formula or calculate a new dose. Ask the prescriber to explain the basis of the decision and whether repeat testing or specialist advice is needed when estimates differ.
Acute illness can change the situation quickly
Acute kidney injury can occur with dehydration, infection, low blood pressure, obstruction or other problems. Symptoms may include passing much less urine, vomiting, swelling, drowsiness or breathlessness, although some people have few symptoms. Suspected acute kidney injury needs medical assessment rather than waiting for the next routine medication appointment. [3]
Tell the team about vomiting, diarrhea, poor intake and recent medicine changes. Ask in advance whether there are medicine-specific instructions for illness. Do not apply a generic sick-day rule to every prescription or drink excessive water to flush a medicine out. People with fluid restrictions need advice that fits their underlying condition.
Lithium requires a clear monitoring plan
Lithium is a prominent example of a medicine whose safety depends on appropriate monitoring. Blood levels, kidney function, thyroid function and other checks are relevant. Interacting medicines and changes in fluid or sodium intake can alter risk. Monitoring should be individualized, with a named clinician responsible for reviewing results. [4]
New coarse tremor, unsteadiness, vomiting, diarrhea, marked drowsiness or mental-state changes can suggest toxicity. Suspected lithium toxicity requires withholding further lithium and urgent assessment. Do not take a recent normal blood result as proof that a new deterioration is harmless. This urgent response is different from a routine decision to discontinue long-term treatment.
Gabapentin and pregabalin
Gabapentin and pregabalin require attention to kidney function. Reduced clearance can affect exposure and tolerability. A switch between them should consider renal function as well as the indication, current regimen and adverse effects. Equal milligram numbers do not represent equivalent treatment. [5]
Report new dizziness, excessive sleepiness or impaired coordination, especially after an illness or another sedating medicine. Both medicines can also cause withdrawal after abrupt changes. The team should address a possible accumulation problem without overlooking the original pain, seizure or anxiety condition. A patient should not be left to choose between toxicity concerns and an unplanned abrupt stop.
Interpreting liver results in context
Liver-related blood tests can reflect different aspects of liver injury or function. An abnormal result needs interpretation alongside symptoms, previous results, other medicines and underlying disease. A mild enzyme rise is not automatically the same as liver failure, but serious or worsening abnormalities must not be dismissed because the person feels well.
Ask what the result means, whether the medicine is a possible contributor and when tests should be repeated. Clarify which symptoms require urgent advice. The review should also consider alcohol, metabolic disease, infections and supplements where relevant. Avoid assuming that stopping one psychiatric medicine will resolve every abnormal test or that a supplement will protect the liver.
Agomelatine has specific liver precautions
Agomelatine requires liver testing before and during treatment and has restrictions in liver disease. EMA guidance emphasizes prompt discontinuation when signs of potential liver injury appear or relevant test abnormalities occur. Its monitoring requirements are not optional simply because the antidepressant is helping. [6]
Dark urine, pale stools, yellow skin or eyes, upper-right abdominal pain or persistent unexplained new tiredness are warning symptoms. Stop agomelatine and seek urgent medical advice if these occur, following its specific safety guidance. Do not wait for a scheduled test or apply a general instruction about gradual antidepressant withdrawal to delay this action. [7]
Valproate and broader physical monitoring
Valproate monitoring includes liver tests and blood-count or clotting considerations. Significant abdominal pain with nausea or vomiting, unexplained bleeding or signs of liver illness need prompt attention. A clinician must interpret the results and decide whether treatment should change. [8]
Valproate can be prescribed for different conditions, so changes may need coordination with neurology or psychiatry. Do not assume that a normal liver test settles every safety issue: reproductive precautions, interactions and the underlying condition remain relevant. The purpose of monitoring is to support a complete treatment decision, not provide a blanket declaration that the medicine is safe indefinitely.
Addiction-treatment medicines and organ health
Alcohol-related illness, opioid exposure and addiction-treatment prescriptions should be included in the same assessment. Medicines such as naltrexone, acamprosate or disulfiram have different organ-function considerations and are not interchangeable solutions. The exact product information, indication and health history determine suitability; one abnormal result cannot choose the appropriate addiction treatment.
Be open about alcohol and other substances, including recent changes. A nonjudgmental account helps clinicians distinguish withdrawal, adverse effects and physical illness. Do not use a general concern about liver health as a reason to attempt an abrupt, unsupported alcohol detox. Withdrawal assessment and continuing addiction care need their own coordinated plan.
Over-the-counter products and supplements
Some pain medicines and other non-prescription products can affect kidney function or interact with psychiatric treatment. Supplements marketed for detoxification or liver support also belong in the medicine list. A natural label does not establish compatibility, and a product advertised as cleansing the body is not a substitute for diagnosing a new symptom or abnormal result.
Ask the pharmacist before adding a product, particularly during illness or after a change in kidney or liver tests. Bring the actual ingredient list where possible. The multiple-medicine review guide can help identify information that might otherwise be missed between specialist appointments.
Blood-level timing and formulation changes
For medicines with measured blood concentrations, the timing of a sample may affect interpretation. Follow the service’s instructions and report when the last dose was actually taken. Do not change the regimen to produce a more reassuring result. A laboratory value without the correct timing and clinical context can be misleading.
Changes between brands, release systems or liquid products may also need attention. Ask the pharmacist to verify the exact formulation and whether extra monitoring is needed. If the supply changes unexpectedly, contact the prescribing team rather than assuming that a matching active ingredient always means identical practical instructions.
Keeping physical and mental health care connected
A new organ-health concern should not lead to the underlying psychiatric condition being forgotten. If a medicine must be changed or withheld, ask how symptoms will be supported and who will monitor the transition. Conversely, severe anxiety or depression should not cause new physical symptoms to be dismissed as psychological without assessment.
Record the reason for any change and share it with the relevant teams. A discharge summary should explain whether a medicine was stopped permanently, withheld during illness or awaiting repeat tests. Without that distinction, another clinician may restart it too soon or leave effective treatment interrupted unnecessarily.
Questions to bring to the review
Ask which results matter for each medicine, what trend the clinician is looking for and who will act on the findings. Clarify the next test date, how results will be communicated and what to do during vomiting, dehydration or another acute illness. A monitoring plan should name responsibilities, not simply say bloods checked.
Bring the actual medication list and a concise symptom timeline. Explain whether the main concern is an adverse effect, a laboratory result or uncertainty about long-term treatment. A useful review may result in further investigation, closer monitoring or a change in treatment. The next step should be understandable and linked to the person’s clinical needs.
Frequently asked questions
Does a renal dose adjustment mean the medicine damaged my kidneys?
Not necessarily. A medicine may need adjustment because an existing or new kidney problem changes clearance. The cause of the kidney problem is a separate clinical question.
Can normal tests rule out every adverse effect?
No. Tests provide specific information at a particular time. New symptoms and changes in other medicines or health still need assessment.
Should all medicines be stopped after an abnormal liver test?
No. The result, symptoms and individual products must be reviewed. Some medicine-specific warnings require urgent stopping action, while other situations call for investigation or planned adjustment.
Evidence and sources
- [1] NHS: Chronic kidney disease diagnosis.
- [2] NHS Specialist Pharmacy Service: Calculating kidney function.
- [3] NHS: Acute kidney injury.
- [4] NHS Specialist Pharmacy Service: Lithium monitoring.
- [5] NHS Specialist Pharmacy Service: Switching gabapentin and pregabalin.
- [6] EMA: Valdoxan.
- [7] MHRA: Agomelatine hepatotoxicity precautions.
- [8] NHS Specialist Pharmacy Service: Valproate monitoring.


